Let's Talk

Opt-in
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is for validation purposes and should be left unchanged.

P3 – and $1M from Johnson & Johnson – power gene therapy workforce development in New Jersey

NJBIZ.com   |   February 05, 2025

Officials gathered Tuesday at Raritan Valley Community College to mark the launch of NJBioFutures.

The public-private partnership aims to create a sustainable, skilled talent pipeline to support the state’s rapidly expanding cell and gene therapeutics sector.

While the industry is growing exponentially, it also faces a shortage of skilled workers to support this expansion.

The design of this new program seeks to help solve that challenge. NJBioFutures brings together experts from education, government and industry, as well as community stakeholders to offer differentiated programs, state-of-the-art facilities and industry-responsive curricula to help build a pipeline in this space.

Johnson & Johnson serves as NJBioFutures founding sponsor, with a $1 million contribution.

With the New Jersey Council of County Colleges (NJCCC) playing a key stakeholder role in the initiative, Raritan Valley Community College (RVCC), Middlesex College (MC) and Mercer County Community College (MCCC) will provide short-and-long-term training and certification programs on cell and gene therapy biomanufacturing, biotechnology and biopharmaceuticals.

Read the full story from NJBIZ here.

Start typing and press enter to search

Scroll to Top